Humana Goes Full Send (+15%) as Medicare’s Former Class Clown Becomes $4.8B Valedictorian

By Stocks News   |   1 month ago   |   Stock Market News
Humana Goes Full Send (+15%) as Medicare’s Former Class Clown Becomes $4.8B Valedictorian

Medicare fraud Medicare honor roll

If you thought the only people celebrating Medicare's annual report cards were retirees comparing prescription drug coverage over a bowl of Quaker oatmeal… allow me to introduce you to Humana shareholders.

Turns out getting straight A's in DC pays a hell of a lot better than getting them in high school.

“Wait… you guys are getting paid for this?” -my 10th-grade self

And by a whole lot, I mean $4.8 billion.

Shares of Humana surged 15% Friday after management revealed that 95% of its Medicare Advantage members will be enrolled in plans receiving at least four stars in 2027.

For comparison, that number was just 20% in 2026.

Yes, folks. Humana just went from the kid repeating third grade to the class valedictorian in twelve months.

Someone check the answer sheet.

So why is Wall Street throwing a parade that puts Macy’s to shame over a freaking Yelp rating?

Glad you asked, you financially curious little degenerate.

Every year, Medicare plays Simon Cowell with private insurers, handing out one to five stars based on patient care, prescription drugs, and whether customer service leaves grandma to rot on hold actually picks up the damn phone.

And unlike your local KFC, where five stars might get you an extra drumstick, Medicare hands its teacher's pets billions in government bonus payments.

Your tax dollars at work, ladies and gentlemen.

J.P. Morgan expected just 60% to 70% of Humana's members to land in highly rated plans.

Instead, Humana delivered 95%.

And the financial implications are enormous.

Evercore ISI analyst Elizabeth Anderson estimates Humana could collect approximately $4.8 billion in quality bonus payments in 2028 thanks to the ratings rebound.

Not bad for a company that spent the last two years getting its teeth kicked in by the very same grading system.

Remember, Humana's previous Medicare ratings were so ugly that the company actually dragged the government into federal court over how its scores were calculated.

It lost that fight.

And earlier this year, management was forced to slash its earnings outlook as weaker ratings threatened its bottom line.

But while Humana was busy pulling off the academic comeback of the century, its competitors were apparently eating glue in the back of the classroom.

According to J.P. Morgan, UnitedHealth Group is expected to see its share of members in highly rated plans tumble from 81% to 67%.

Harvard called. They want their rejection letter back.

Meanwhile, CVS Health is projected to drop from 84% to 70%.

And here's the part that'll really knock your deductible-covered socks off.

Humana's improved healthcare ratings came with some actual (wait for it) healthcare improvements.

Humana says its efforts to improve member care helped 28,000 people receive overdue mammograms, identifying 600 previously undetected breast cancers.

Another 93,000 members completed overdue colorectal screenings, uncovering approximately 100 cases of cancer or precancerous conditions.

Imagine that. The secret to better healthcare ratings was better healthcare.

Unfortunately, Humana's $4.8 billion sugar daddy has a bit of a commitment problem.

Donnie Politics is promising the money now… but won't put out until 2028.

And analysts at Baird warn that not every dollar will necessarily become profit, since Humana may need to reinvest portions into member benefits and payments to healthcare providers.

Still, quite the comeback for a company whose last two years consisted of lousy Medicare grades, earnings disasters, and getting its ass handed to it in federal court. 

And with Medicare's annual enrollment period kicking off October 15, the company gets to parade its new report card in front of millions of potential customers.

Hide your grandmas.

At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer